Valuation: ASKA Pharmaceutical Holdings Co.,Ltd.

Market Cap 5.7TCr 36Cr 32Cr 30Cr 27Cr 51Cr 3.45TCr 52Cr 360.63Cr 142.78Cr 1.81TCr 136.33Cr 133.43Cr P/E 2027 *
12.2x
P/E 2028 * 10.3x
Enterprise Value 5.7TCr 36Cr 32Cr 30Cr 27Cr 51Cr 3.45TCr 52Cr 360.63Cr 142.78Cr 1.81TCr 136.33Cr 133.43Cr EV / Sales 2027 *
0.78x
EV / Sales 2028 * 0.76x
Free-Float
64.59%
Yield 2027 *
3.24%
Yield 2028 * 3.49%
04/09 Metagen Therapeutics, Inc. announced that it has received ¥3.71 billion in funding from a group of investors CI
04/08 ASKA Pharmaceutical Holdings Co.,Ltd. Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
25/06 Declaration of Voting Results by Asuka Pharmaceutical CI
27/05 Dalton Investment strongly oppose conditional activation of countermeasures announced by ASKA Pharmaceutical Holdings on May 25 RE
25/05 Aska pharmaceutical - plan to put to shareholders proposal on countermeasures against potential large-scale share purchase by Dalton and related parties RE
12/05 Asuka Pharmaceutical Opposes Nippon Active Value Fund Plc?s Shareholder Proposal for Board Changes at 2026 Annual Meeting CI
11/05 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Change in Dividend Policy CI
11/05 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
11/05 ASKA Pharmaceutical Holdings Co.,Ltd. Proposes Year-End Dividend for Fiscal Year Ended March 31, 2026, Payable on June 25, 2026; Provides Dividend Guidance for End of Second Quarter of Fiscal Year Ending March 31, 2027 CI
11/05 ASKA Pharmaceutical Holdings Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2027 CI
11/05 ASKA Pharmaceutical Holdings Co.,Ltd. Announces Retirement of Kazuhiro Chiku as Audit & Supervisory Board Member, Effective June 24, 2026 CI
14/04 FTS AMBROSE HOLDINGS, INC. announced that it has received funding from ASKA Pharmaceutical Holdings Co.,Ltd. CI
24/03 Insilico Medicine And ASKA Pharmaceutical Enter Strategic Research Collaboration For Women's Health CI
1 day-1.13%
1 week-1.57%
Current month-2.43%
1 month-6.09%
3 months-10.04%
6 months-32.95%
Current year-1.57%
1 week 1,996
Extreme 1996
2,049
1 month 1,975
Extreme 1975
2,165
Current year 1,917
Extreme 1917
3,045
1 year 1,917
Extreme 1917
3,045
3 years 1,675
Extreme 1675
3,045
5 years 919
Extreme 919
3,045
10 years 776
Extreme 776
3,045
Manager TitleAgeSince
Chief Executive Officer - -
President 42 24/06/2025
Chief Administrative Officer - -
Director TitleAgeSince
Chairman 74 24/06/2025
Director/Board Member 67 01/04/2021
Director/Board Member 42 01/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-1.57%-7.39%+17.79% 36Cr
-2.54%+1.31%+54.27%+114.96% 1,13500Cr
-1.42%+3.23%+38.56%+74.44% 64TCr
+0.16%+0.08%+25.29%+95.23% 50TCr
-0.31%+3.09%+44.14%+64.80% 38TCr
-1.34%-0.47%+66.04%+41.00% 36TCr
-0.68%+2.65%+22.98%+50.39% 29TCr
-1.20%+3.04%+2.33%+22.86% 27TCr
-1.79%+1.57%+50.56%+59.08% 24TCr
-0.73%-0.10%+29.02%+99.67% 19TCr
Average -1.10%+1.79%+32.58%+64.02% 40.04TCr
Weighted average by Cap. -1.35%+2.66%+41.02%+79.75%

Financials

2027 *2028 *
Net sales 7.31TCr 47Cr 42Cr 38Cr 35Cr 65Cr 4.43TCr 66Cr 462.94Cr 183.28Cr 2.32TCr 175.01Cr 171.29Cr 7.5TCr 48Cr 43Cr 39Cr 36Cr 67Cr 4.54TCr 68Cr 474.53Cr 187.87Cr 2.38TCr 179.39Cr 175.58Cr
Net income 466.9Cr 2.98Cr 2.66Cr 2.46Cr 2.23Cr 4.16Cr 282.66Cr 4.23Cr 30Cr 12Cr 148.09Cr 11Cr 11Cr 552.4Cr 3.52Cr 3.15Cr 2.91Cr 2.63Cr 4.93Cr 334.42Cr 5.01Cr 35Cr 14Cr 175.21Cr 13Cr 13Cr
Net Debt - -
Projected Income Statement - Annual - ASKA Pharmaceutical Holdings Co.,Ltd.
Logo ASKA Pharmaceutical Holdings Co.,Ltd.
ASKA Pharmaceutical Holdings Co Ltd is a Japan-based company primarily engaged in the pharmaceutical business. The Company has three business segments. The Pharmaceutical Business segment primarily manufactures and sells prescription pharmaceuticals. The Animal Health Business segment primarily manufactures and sells veterinary medicines, feed additives, and other products. The Overseas Business segment primarily manufactures and sells prescription pharmaceuticals overseas. The Company also engages in clinical testing and medical equipment businesses.
Employees
1,611
Date Price Change Volume
23/26/23 JP¥2,006.00 -1.13% 52,300
22/26/22 JP¥2,029.00 +0.20% 53,700
21/26/21 JP¥2,025.00 +1.05% 67,200
20/26/20 JP¥2,004.00 -1.09% 46,100
19/26/19 JP¥2,026.00 -0.59% 72,700
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - ASKA Pharmaceutical Holdings Co.,Ltd.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2,006.00JPY
Average target price
2,400.00JPY
Spread / Average Target
+19.64%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ASKA Pharmaceutical Holdings Co.,Ltd.
  1. Stock Market
  2. Stocks
  3. 4886 Stock